Member Info for BuenaVista

Not until it's inked. And do both parties have to agree to the announcement and the extent of the details in the announcement?

Well, not the RNS I was expecting today - that was about the trial or the announcement of the AGM - and a bit out of left field. However I conclude, as others have, that this evaluation would only have been considered (starting some time ago) if funding for the AVA6000 trial was not assured from some source, and it is natural to assume that that source is licensing that has been in negotiation for some time.

I'm not surprised. Avacta obviously doesn't have the know-how to develop LFTs in-house. Over a year and absolutely no news of the development of any tests for the list of announced intended targets. Maybe Coris can do something with Affimers.

The biotech sector is suffering generally. Inflation, interest rates, cost of loans, that sort of thing.

Lol @Shamtown,

You realise that is a video from a channel that is a mouthpiece for the livestock lobby?

Now, a question for you Shamtown. Do you know the problems (plural) with conventional lab meat that 3D Bio-Tissues addresses and solves?

Well the business model is to sell the tech, City-Mix, for meat production out for others to do the manufacturing rather than do it in-house isn't it? In which case, I hope it'll be more than one large manufacturer!

2017. Jeez. So slow.

Anticlimactic, yes. but a great buying opportunity. MMs are collecting shares from an engineered drop that they'lll make a big profit on when the price rises, be it an engineered rise or a real one.

Hooray!!!!!!!!!!! The eejits have thrown themselves into another bore-centric yawn.🥱 Yet again.🙄 Really children, grow up.🤡🤡🤡

It's time for you to sell up then Terry and leave this BB. Goodbye.

@steven49, what do you see as the hurdles to 'cross'?

The size issue... I wonder what the graph of cost per cm³ of unblemished meat looks like. Cost to include the time the equipment is tied up producing the meat. There are alternative forms of meat though, namely minced meat and however the noodle is produced (in a mould or by 'extrusion'?) Competition for minced meat would be against low or lower quality pig meat though so would have to sell on USP of ethics or quality.

Does anyone know why culturally restricted pork was chosen for this over more widely accepted, and from what I remember more expensive, lamb or even beef?

MMs really working hard on dropping the price to scare holders into selling. I'm expecting this to rise considerably over the rest of this week.

The key (haha!) part of the invention is the -D-Ala-L-Pro- link in the substrate that can be cleaved (hydrolysed, split with the addition of -OH and -H) by FAP. The leaving group is the bit that fits inside the FAP pocket and has to have certain characteristics that will fix the substrate in position, typically the forming of hydrogen bonds and electrostatic attraction. For example, a long hydrocarbon chain, -(CH2)n-CH3, would not do the job (wouldn't fit), nor would just a methyl group, -CH3 (loss of specificity).

It is the fit of the leaving group that makes the substrate specific for FAP which is why I do not understand why two versions are in play except that maybe both are equally good or each is better for the prodrug it is attached to. If there are other leaving groups, which other companies might try, the invention is protected because the key part is the -D-Ala-L-Pro- link.

Just filter the sealion and all those who taunt or engage with him as those posters never add anything in the way of insight, information or interpretation. Makes the board very green but doesn't miss anything important.

Who's stressing? I think you've posted to the wrong thread.

All good points.

I have no particular experience or knowledge in this field but I feel that if C5 has gone this far (51 days), then the liklihood is that MTD has not been found yet and is unlikely to be found and we can expect the announcement of C6 soon, next week if there were no dropouts from C5.

@Olderandwiser

The "giddy height of £2, where it was in 2001 briefly". What are you on about? I guess you are doing a MCap calculation and that wasn't a typo because the SP was way above £2 in 2021 when the PIs dived in in the hope of feeding on a Covid bonanza. Do you think Avacta was a better commercial proposition in 2001, or even 2021, than it is now in 2023?

No trades yet on OTCQB. Hopefully the showcase event will garner some interest.

https://www.marketwatch.com/investing/stock/bsfaf?mod=mw_quote_tab

I disagree. The leaving group is the 'key' par tof the substrate that fits into the FAP 'lock', and only the FAP lock, so perfectly that it conveys the specificity we see. The commom feature of this key is the D-Ala-L-Pro part. I'm not understanding why the leaving group needs to be varied let alone why even more need to used. There is nothing that says whatever is on the D-Ala end of the leaving group will be biochemically inactive - so why use different leaving groups? It just seems to be adding an extrra level of complexity and leaving the door open for unexpected consequences, not just during trials but more importantly in a marketed drug used by millions where the rare adverse reactions become apparent.